Clinical-stage biotechnology company Wave Life Sciences Ltd. (WVE) continues to build momentum across its RNA editing and silencing programs, with multiple clinical and preclinical milestones expected before the end of 2025.
The company's pipeline is anchored by WVE-006, a GalNAc-conjugated A-to-I RNA editing oligonucleotide being evaluated in the Phase 1b/2a RestorAATion-2 study for alpha-1 antitrypsin deficiency (AATD).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com